Article Figures & Data
Figures
- Figure 1.
Flowchart of cohort creation
AF—atrial fibrillation, CPCSSN—Canadian Primary Care Sentinel Surveillance Network, DVT—deep vein thrombosis, INR—international normalized ratio, PE—pulmonary embolism.
- Figure 2.
Proportion of TTR for A) the 13 481 patients taking warfarin (with an INR target range of 2.0 to 3.5) and B) the 5556 patients taking warfarin with known AF, DVT, or PE (with an INR target range of 2.0 to 3.0): Both were determined over the 2008 to 2016 study period.
AF—atrial fibrillation, DVT—deep vein thrombosis, INR—international normalized ratio, PE—pulmonary embolism, TTR—time in therapeutic range.
- Figure 3.
Predictive value of baseline TTR: The top histograms are year 1 of warfarin use, with blue indicating good INR control, white intermediate INR control, and yellow poor INR control. The bottom histograms show the distribution of the same patients in year 2 with the same colour coding (eg, the second all-blue histograms show the TTR distribution in year 2 for all patients whose TTR was > 75% in year 1). N = 8054.
AF—atrial fibrillation, DVT—deep vein thrombosis, INR—international normalized ratio, PE—pulmonary embolism, TTR—time in therapeutic range.
- Figure 5.
Distribution of INR readings and all recorded INR values from October 2009 to October 2010 in patients with AF, DVT, or PE taking warfarin: Dark blue indicates INR values out of the low-risk range. Light blue is above the presumed 2.0 to 3.0 target for patients with these indications but within the low-risk range. N = 2184.
AF—atrial fibrillation, DVT—deep vein thrombosis, INR—international normalized ratio, PE—pulmonary embolism.
Tables
PATIENT CHARACTERISTICS ALL WARFARIN USERS (N = 13 481) THOSE WITH AF (N = 5010) THOSE WITH VTE (N = 730) Female sex, n (%) 6285 (46.6) 2221 (44.3) 379 (51.9) Mean (SD) age, y 71.9 (14.0) 75.1 (11.3) 63.1 (15.9) Mean (SD) BMI, kg/m2 30.1 (6.8) 30.2 (6.5) 31.8 (7.3) Mean (SD) GFR, mL/min 64.7 (19.9) 58.2 (16.7) 56.3 (17.7) Comorbidities, n (%) • Hypertension 8103 (60.1) 3349 (66.9) 370 (50.7) • Osteoarthritis 4852 (36.0) 2149 (42.9) 288 (39.5) • Diabetes 4144 (30.7) 1670 (33.3) 178 (24.4) • Depression 3075 (22.8) 1061 (21.2) 233 (31.9) • COPD 2747 (20.4) 1146 (22.9) 125 (17.1) • Dementia 1770 (13.1) 731 (14.6) 62 (8.5) Warfarin-related condition, n (%) • AF 5010 (37.2) 5010 (100.0) 184 (25.2) • DVT 621 (4.6) 160 (3.2) 621 (85.1) • PE 131 (1.0) 33 (0.7) 131 (18.0) Medications, n (%) • ≥ 4 medications (including warfarin) 7120 (52.8) 2807 (56.0) 292 (40.0) • Cardiovascular drugs 9973 (74.0) 4179 (83.4) 340 (46.6) • Lipid-modifying drugs 5779 (42.9) 2187 (43.7) 179 (24.5) • Drugs for acid disorders 4323 (32.1) 1707 (34.1) 202 (27.7) • Drugs for COPD or asthma 3085 (22.9) 1213 (24.2) 134 (18.4) • Antidepressants 2961 (22.0) 1029 (20.5) 186 (25.5) • Thyroid-related drugs 1975 (14.7) 799 (16.0) 73 (10.0) • Antiepileptics 1743 (12.9) 660 (13.2) 125 (17.1) • Anxiolytics 1510 (11.2) 510 (10.2) 62 (8.5) • ASA 967 (7.2) 499 (10.0) 39 (5.3) • Other antiplatelets 457 (3.4) 165 (3.3) 10 (1.4) • Psycholeptics 576 (4.3) 196 (3.9) 46 (6.3) • Anti-dementia drugs 381 (2.8) 132 (2.6) 5 (0.7) AF—atrial fibrillation, ASA—acetylsalicylic acid, BMI—body mass index, COPD—chronic obstructive pulmonary disease, DVT—deep vein thrombosis, GFR—glomerular filtration rate, PE—pulmonary embolism, VTE—venous thromboembolism.
CFPlus Additional Information
In this issue
